2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
543
Squamous Cell Carcinoma of Head and Neck
280
Head and Neck Neoplasms
257
Lung Neoplasms
240
Uterine Cervical Neoplasms
180
Stomach Neoplasms
172
Esophageal Neoplasms
161
Nasopharyngeal Carcinoma
127
Urinary Bladder Neoplasms
117
Neoplasms
115
Esophageal Squamous Cell Carcinoma
115
Small Cell Lung Carcinoma
105
Ovarian Neoplasms
92
Breast Neoplasms
92
Neoplasm Metastasis
89
Cholangiocarcinoma
76
Carcinoma, Squamous Cell
76
Pancreatic Neoplasms
72
Biliary Tract Neoplasms
71
Oropharyngeal Neoplasms
57
Mesothelioma, Malignant
57
Carcinoma
55
Adenocarcinoma Of Esophagus
52
Recurrence
48
Parkinson Disease 4, Autosomal Dominant Lewy Body
47
Carcinoma, Ovarian Epithelial
46
Nasopharyngeal Neoplasms
41
Lymphoma
41
Adenocarcinoma of Lung
41
Gallbladder Neoplasms
39
Interventions
pembrolizumab
3
Pemetrexed
2
Cholecalciferol
2
vorasidenib
1
relacorilant
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
bosutinib
1
Trastuzumab
1
Sunitinib
1
Morphine
1
Methadone
1
MRX-2843
1
Letrozole
1
Imatinib Mesylate
1
Electrochemotherapy
1
Control Groups
1
Clomiphene
1
Cisplatin
1
Carboplatin
1
Bleomycin
1
Bevacizumab
1
Azacitidine
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Cisplatin
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled